News | July 11, 2023
Sumitomo Pharma America launches as new combined organization
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Advances clinical research capabilities with leading regulatory grade registries platform
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Cipla has a robust governance model focused on sustainability
PEEK brings a new quality to dental care for patients
Subscribe To Our Newsletter & Stay Updated
